Literature DB >> 12835670

Ovarian cancer: strategies for overcoming resistance to chemotherapy.

Roshan Agarwal1, Stan B Kaye.   

Abstract

Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835670     DOI: 10.1038/nrc1123

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  425 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

2.  Establishment of a New Ovarian Cancer Cell Line CA5171.

Authors:  Ying-Cheng Chiang; Wen-Fang Cheng; Ming-Cheng Chang; Tzu-Pin Lu; Kuan-Ting Kuo; Hsiu-Ping Lin; Chang-Yao Hsieh; Chi-An Chen
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

3.  Isolation and characterization of stem-like cells from a human ovarian cancer cell line.

Authors:  Lijuan Wang; Roman Mezencev; Nathan J Bowen; Lilya V Matyunina; John F McDonald
Journal:  Mol Cell Biochem       Date:  2011-12-09       Impact factor: 3.396

4.  Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Authors:  Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner
Journal:  Mol Cancer Res       Date:  2019-01-03       Impact factor: 5.852

5.  Targeted delivery of platinum-taxane combination therapy in ovarian cancer.

Authors:  Swapnil S Desale; Kruti S Soni; Svetlana Romanova; Samuel M Cohen; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-09-14       Impact factor: 9.776

Review 6.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

7.  Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.

Authors:  Wei Li; Zhong-lei Ji; Guang-chao Zhuo; Ru-jun Xu; Jie Wang; Hong-ru Jiang
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

8.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Authors:  Nuo Yang; Sippy Kaur; Stefano Volinia; Joel Greshock; Heini Lassus; Kosei Hasegawa; Shun Liang; Arto Leminen; Shan Deng; Lori Smith; Cameron N Johnstone; Xian-Ming Chen; Chang-Gong Liu; Qihong Huang; Dionyssios Katsaros; George Adrian Calin; Barbara L Weber; Ralf Bützow; Carlo M Croce; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

10.  Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model.

Authors:  Ming Yang; Tao Yu; Joseph Wood; Ying-Ying Wang; Benjamin C Tang; Qi Zeng; Brian W Simons; Jie Fu; Chi-Mu Chuang; Samuel K Lai; T-C Wu; Chien-Fu Hung; Justin Hanes
Journal:  Drug Deliv Transl Res       Date:  2014-04-01       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.